TEMPEST THERAPEUTICS INC (TPST)

Company Profile

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development and discovery of small molecule drugs for the treatment of cancer. The company is headquartered in Brisbane California, California and currently employs 19 full-time employees. The company went IPO on 2012-10-04. The firm is focused on developing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a range of tumors. The Company’s two clinical programs include TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPARa). TPST-1120 is in Phase I and II trials in solid tumors, including a global randomized Phase Ib/II trial in combination with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, and is in Phase I monotherapy and combination trials in solid tumors.

Company Info

TEMPEST THERAPEUTICS INC

2000 Sierra Point Parkway, Suite 400

Brisbane California CALIFORNIA

P: 14157988589

CEO: Louis Arcudi

Employees: 19

Website: https://www.tempesttx.com/